SEARCH
Search Details
Sugawara-Suda Mei
| Faculty of Veterinary Medicine Veterinary Teaching Hospital | Specially Appointed Assistant Professor |
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
ORCID IDJ-Global ID■ Research Keywords and Fields
Research Keyword■ Educational Organization
- Bachelor's degree program, School of Veterinary Medicine
- Doctoral (PhD) degree program, Graduate School of Veterinary Medicine
Research activity information
■ Awards- Feb. 2020, 第16回日本獣医内科学アカデミー学術大会（JCVIM2020）, 臨床研究アワード（インターズー学術奨励賞）
非再生性貧血のミニチュア・ダックスフンド11例に対する脾臓摘出術の治療成績
菅原芽伊, 森下啓太郎, 今井 健友, 山崎 淳平, 佐々木 東, 大田 寛, 細谷 謙次, 滝口 満喜
- Evaluation of the course of improvement with molnupiravir treatment for feline infectious peritonitis.
Shino Yoshida; Mei Sugawara-Suda; Kazuyoshi Sasaoka; Noboru Sasaki; Nozomu Yokoyama; Kensuke Nakamura; Keitaro Morishita; Sangho Kim; Takafumi Sunaga; Mitsuyoshi Takiguchi
The Canadian veterinary journal = La revue veterinaire canadienne, 66, 5, 546, 554, May 2025, [International Magazine]
English, Scientific journal, OBJECTIVE: To clarify the clinical course during molnupiravir treatment for feline infectious peritonitis (FIP). ANIMALS AND PROCEDURE: Cats diagnosed with FIP and treated with molnupiravir at Hokkaido University Veterinary Teaching Hospital (Sapporo, Hokkaido, Japan) were retrospectively reviewed. RESULTS: Eleven cats were eligible for inclusion. Six cats had effusive FIP and 5 had non-effusive FIP. In noneffusive cases, 2 cats had neurological abnormalities at diagnosis, whereas 1 additional cat developed neurological signs during treatment. The median initial dosage of molnupiravir was 13.0 mg/kg (range: 10.0 to 15.0 mg/kg), PO, q12h. One cat died after 11 d and the remaining 10 cats completed an 84-day course of treatment. All neurological cases were given dosage increases, extended treatment duration, or both. The median final dosage of molnupiravir in non-neuro-FIP cases was 13.1 mg/kg (range: 10.0 to 15.0 mg/kg), PO, q12h, whereas dosages in neuro-FIP cases were 15.0, 15.2, and 17.2 mg/kg, PO, q12h in the 3 affected cats, respectively. In non-neurological cases, dysrexia, lethargy, and high serum amyloid A were resolved within 15 d. Total follow-up duration ranged from 175 to 362 d. No relapses were observed. CONCLUSION AND CLINICAL RELEVANCE: Monitoring responses to molnupiravir treatment requires observing clinical signs and conducting clinicopathological evaluations, including acute-phase protein evaluation. - Investigation of the therapeutic effects, predictors, and complications of long-term immunosuppressive therapy in dogs with precursor-targeted immune-mediated anemia.
Mei Sugawara-Suda; Keitaro Morishita; Yuto Iwanaga; Jumpei Yamazaki; Yumiko Kagawa; Nozomu Yokoyama; Noboru Sasaki; Hiroshi Ohta; Kensuke Nakamura; Mitsuyoshi Takiguchi
The Journal of veterinary medical science, 85, 7, 695, 701, 01 Jul. 2023, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Dogs with precursor-targeted immune-mediated anemia (PIMA) are commonly treated with immunosuppressive therapy, but information on predictors of treatment response and response time is limited. Therefore, we retrospectively investigated predictive factors that influenced the treatment response and duration required to observe a response in dogs with PIMA receiving continuous immunosuppressive therapies for more than 105 days. Of 50 client-owned dogs that developed PIMA, 27 were included in this study, of which 18 were responders and 9 were non-responders to immunosuppressive therapies. Sixteen of the 18 responders responded to treatment within 60 days and the remaining 2 responded at 93 and 126 days, respectively. We found that an erythroid-maturation ratio of <0.17 may be a useful predictor for treatment response. In addition, complications of immunosuppressive therapies were investigated further in 50 dogs. Pancreatitis (n=4) and pneumonia (3) occurred over the entire treatment period, and infections such as abscesses (3) tended to be more common in dogs on an extended period of immunosuppressive therapy. These findings may be helpful when planning for the initial treatment and may provide evidence for informed consent about potential comorbidities throughout the treatment course. - Evaluation of responses to immunosuppressive therapy in dogs with suspected non‐regenerative immune‐mediated anaemia: 11 cases (2012‐2018)
K. Morishita; M. Sugawara‐Suda; J. Yamazaki; N. Sasaki; K. Nakamura; H. Ohta; M. Takiguchi
Journal of Small Animal Practice, 64, 8, 527, 534, Wiley, 07 Apr. 2023
Scientific journal, Objectives
We aimed to determine the response time to immunosuppressive therapy and time required to achieve a 5% increase in haematocrit among dogs with non‐regenerative immune‐mediated anaemia.
Materials and Methods
Client‐owned dogs diagnosed with non‐regenerative immune‐mediated anaemia in Hokkaido University Veterinary Teaching Hospital between December 2012 and May 2018 were enrolled. The first treatment regimen included prednisolone (2 mg/kg/day) and ciclosporin (up to 10 mg/kg/day) for 8 weeks. Dogs that did not respond to the first regimen proceeded to the second regimen comprising prednisolone and mycophenolate mofetil (15 mg/kg, twice a day). Reticulocyte count and haematocrit were monitored every 1 to 2 weeks. Treatment response was defined as an absolute reticulocyte count more than 60×103/μL or increasing haematocrit.
Results
During the study period, 23 dogs fulfilled the inclusion criteria for non‐regenerative immune‐mediated anaemia. Twelve dogs were excluded from this study for various reasons and response to therapy was evaluated in the remaining 11 dogs. Treatment responses were observed in 8 of 11 dogs, and the median time to response was 39.5 days (range 8 to 92 days). Two responders were unable to continue the first treatment regimen and were switched to the second regimen owing to anorexia and nausea, possibly induced by ciclosporin; withdrawal of ciclosporin improved their symptoms. The time required to achieve a 5% increase in haematocrit was assessed in the other six dogs, with a median of 55.5 days (range 8 to 135 days).
Clinical Significance
Here we report the response to a standardised treatment protocol in dogs with non‐regenerative immune‐mediated anaemia. Knowledge of potential side effects and expected therapeutic outcomes may be of use for veterinary practitioners treating this condition. - Transcriptome and proteome analysis of dogs with precursor targeted immune-mediated anemia treated with splenectomy.
Mei Sugawara-Suda; Keitaro Morishita; Osamu Ichii; Takashi Namba; Keisuke Aoshima; Yumiko Kagawa; Sangho Kim; Kenji Hosoya; Nozomu Yokoyama; Noboru Sasaki; Kensuke Nakamura; Jumpei Yamazaki; Mitsuyoshi Takiguchi
PloS one, 18, 5, e0285415, 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, Precursor-targeted immune-mediated anemia (PIMA) in dogs is characterized by persistent non-regenerative anemia and ineffective erythropoiesis, and it is suspected to be an immune-mediated disease. Most affected dogs respond to immunosuppressive therapies; however, some are resistant. In this study, we carried out splenectomy as an alternative therapy for refractory PIMA in dogs, and analyzed gene expression levels in the spleen of dogs with or without PIMA and in serum before and after splenectomy. A total of 1,385 genes were found to express differentially in the spleens from dogs with PIMA compared with healthy dogs by transcriptome analysis, of which 707 genes were up-regulated, including S100A12, S100A8, and S100A9 that are linked directly to the innate immune system and have been characterized as endogenous damage-associated molecular patterns. Furthermore, immunohistochemistry confirmed that S100A8/A9 protein expression levels were significantly higher in dogs with PIMA compared with those in healthy dogs. A total of 22 proteins were found to express differentially between the serum samples collected before and after splenectomy by proteome analysis, of which 12 proteins were up-regulated in the samples before. The lectin pathway of complement activation was identified by pathway analysis in pre-splenectomy samples. We speculated that S100A8/9 expression may be increased in the spleen of dogs with PIMA, resulting in activation of the lectin pathway before splenectomy. These findings further our understanding of the pathology and mechanisms of splenectomy for PIMA. - 非再生性免疫介在性貧血の犬における脾臓摘出術前後の血清中蛋白の網羅的解析
菅原 芽伊; 山崎 淳平; 森下 啓太郎; 金 尚昊; 細谷 謙次; 佐々木 東; 中村 健介; 滝口 満喜
日本獣医学会学術集会講演要旨集, 164回, [HSO, 60], (公社)日本獣医学会, Sep. 2021
Japanese - Long-Term Observation of the Progression From Nodal Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma in a Dog
Takanori Shiga; James K. Chambers; Mei Sugawara; Yuko Goto-Koshino; Hajime Tsujimoto; Hiroyuki Nakayama; Kazuyuki Uchida
Veterinary Pathology, 57, 4, 520, 524, SAGE Publications, 17 Jun. 2020, [Peer-reviewed]
Scientific journal, A 4-year and 10-month old female Pembroke Welsh Corgi presented with an enlarged right popliteal lymph node, and a histopathological diagnosis of nodal marginal zone lymphoma (nMZL) was made. After resection of the lymph node, follow-up observation was continued without chemotherapy. At 22 months after initial presentation, the dog developed enlargement of peripheral lymph nodes, and the histopathological diagnosis was late-stage nMZL. Multidrug chemotherapy induced clinical complete remission, but the tumor relapsed with enlargement of peripheral and abdominal lymph nodes 42 months after initial presentation. Second-round multidrug chemotherapy induced complete clinical remission again; however, the tumor relapsed with lymphadenopathy 47 months after initial presentation. The dog died 59 months after initial presentation, and postmortem examination revealed generalized lymphadenopathy; the histopathological diagnosis was diffuse large B-cell lymphoma (DLBCL). Polymerase chain reaction for antigen receptor gene rearrangements revealed that the nMZL and DLBCL samples were derived from the same B-lymphocyte clone. - Blastic natural killer cell lymphoma/leukaemia in a cat
Miyuki Hirabayashi; James K Chambers; Mei Sugawara; Aki Ohmi; Hajime Tsujimoto; Hiroyuki Nakayama; Kazuyuki Uchida
Journal of Feline Medicine and Surgery Open Reports, 5, 2, 205511691986308, 205511691986308, SAGE Publications, 11 Jul. 2019, [Peer-reviewed]
Scientific journal, Case summary
A 7-year-old mixed-breed cat presented with subcutaneous oedema and erythema extending from the right axilla to the abdomen. Fine-needle aspiration of the subcutaneous lesion revealed large, atypical, round cells. A clonality analysis for the T-cell receptor-gamma and immunoglobulin heavy chain genes showed no clonal rearrangement. The presumed diagnosis was lymphoma and the cat was treated with prednisolone and L-asparaginase but died 78 days after initial treatment. At necropsy, an oedematous subcutaneous mass in the right axilla, hepatomegaly, splenomegaly and lymphadenopathy of the mediastinum and left axilla were observed. Histopathological examination revealed diffuse infiltration of large atypical round cells in the subcutaneous mass, liver, spleen, lymph nodes and bone marrow. Immunohistochemically, the tumour cells were strongly positive for CD56, and negative for CD3, CD20, CD79a, CD57, granzyme B and perforin. Based on these findings, the cat was diagnosed with blastic natural killer (NK) cell lymphoma/leukaemia.
Relevance and novel information
Here, we report the pathological and clinical findings of NK cell lymphoma/leukaemia in a cat. The antibody for human CD56, a diagnostic marker for human NK cell neoplasms, showed cross-reactivity with feline CD56 by immunohistochemistry and Western blotting analysis. The antibody could be a useful diagnostic marker for feline NK cell neoplasms.
- やさしく学べる 血液疾患診療教室 PIMA/NRIMA・PRCA
菅原 芽伊, 月刊CAP: Companion Animal Practice, 429, 54, 61, Mar. 2025 - 急性骨髄性白血病
菅原 芽伊, Veterinary Oncology, 12, 1, 25, 34, Jan. 2025 - 嚥下困難を認め輪状咽頭アカラシアと診断した犬の一例
菅原 芽伊, Veterinary Board, 63, 32, 37, Jul. 2024
Japanese - 猫の心筋症における左房ブースターストレインの有用性の検討
佐藤景; 中村健介; 川元誠; 菅原芽伊; 笹岡一慶; 横山望; 佐々木東; 森下啓太郎; 滝口満喜, 日本獣医循環器学会抄録(CD-ROM), 121st, 2024 - 気管支拡張症の原因として気管支軟骨の低形成が疑われた2頭のアメリカン・コッカー・スパニエル
川上侑記; 中村健介; 菅原芽伊; 新坊弦也; 山根由久; 細谷謙次; 岡田一喜; 賀川由美子; 滝口満喜, 北海道獣医師会雑誌, 68, 8, 2024 - 深掘り!赤血球増加症 症例報告3):複数回の瀉血のみで赤血球増加症が寛解した犬の一例
菅原 芽伊, Veterinary Board, 4, 5, 40, 44, 15 May 2022 - 深掘り!赤血球増加症 猫の真性赤血球増多症に対するオニオンパウダーを用いた新しい治療法の1例
菅原 芽伊, Veterinary Board, 4, 5, 56, 57, 15 May 2022 - Comprehensive analysis of steroid profile in dogs with Cushing' syndrome and hepatocellular carcinoma(和訳中)
Oo Thandar; 佐々木 東; 池中 良徳; 永田 矩之; 一瀬 貴大; Bin Teoh Yong; 川元 誠; 小島 一輝; 菅原 芽伊; 中山 翔太; 石塚 真由美; 中村 健介; 滝口 満喜, 日本獣医学会学術集会講演要旨集, 164回, [HSO, 18], Sep. 2021
(公社)日本獣医学会, English - 非再生性免疫介在性貧血の犬における脾臓摘出術前後の血清中蛋白の網羅的解析
菅原 芽伊; 山崎 淳平; 森下 啓太郎; 金 尚昊; 細谷 謙次; 佐々木 東; 中村 健介; 滝口 満喜, 日本獣医学会学術集会講演要旨集, 164回, [HSO, 60], Sep. 2021
(公社)日本獣医学会, Japanese - 非再生性貧血のミニチュア・ダックスフンド11例に対する脾臓摘出術の治療成績
菅原芽伊; 森下啓太郎; 今井健友; 山崎淳平; 佐々木東; 大田寛; 細谷謙次; 滝口満喜, SA Medicine, 22, 3, 74, 75, 01 Jun. 2020 - 輸血のABCと副反応 血液 症例報告 3):遅発性溶血性輸血反応が疑われた症例
菅原 芽伊, Veterinary Board, 2, 1, 40, 45, 15 Jan. 2020
- 犬のさまざまな血液腫瘍における抗原発現パターンおよびリンパ球抗原レセプター遺伝子再構成の検討
鶴田 匠; 稲積 遥; 後藤 裕子; 富安 博隆; 酒井 秀夫; 井手 香織; 笠原 幸一; 辻本 元; 原田 慶; 水野 拓也; 小林 哲也; 高橋 雅; 瀬戸口 明日香; 森下 啓太郎; 菅原 芽伊; 檜野 弘明; 佐々木 悠; 久末 正晴; 高橋 一成; 福岡 玲; 大参 亜紀; 高橋 尚大; 奧田 優
第21回日本獣医内科学アカデミー, 15 Feb. 2025
14 Feb. 2025 - 16 Feb. 2025 - 片側性大脳皮質形成異常症（脳室周囲異所性灰白質、多小脳回）のてんかん犬の一例
郭 乃瑜; 笹岡 一慶; 福山 容一; 新坊 弦也; 菅原 芽伊; 横山 望; 佐々木 東; 森下 啓太郎; 中村 健介; 滝口 満喜
第21回日本獣医内科学アカデミー, 15 Feb. 2025
14 Feb. 2025 - 16 Feb. 2025 - 貧血のとき、検査結果とその解釈〜CBC指標、鉄、フェリチンの活かし方〜
菅原 芽伊
第21回日本獣医内科学アカデミー, 15 Feb. 2025, Japanese
14 Feb. 2025 - 16 Feb. 2025, [Invited] - ITP診断コンセンサス
菅原 芽伊
第21回日本獣医内科学アカデミー, 14 Feb. 2025, Japanese
14 Feb. 2025 - 16 Feb. 2025, [Invited] - メチル化阻害薬による治療を試みた 赤白血病の猫の１例
菅原 芽伊; 山崎 淳平; 森下啓太郎
第30回 日本獣医がん学会, 06 Jul. 2024, 日本獣医がん学会
06 Jul. 2024 - 07 Jul. 2024, 東京, Japan - Treatment Response, Course of Improvement, and Follow-up Information with Molnupiravir Treatment for Feline Infectious Peritonitis
Shino Yoshida; Mei Sugawara; Kazuyoshi Sasaoka; Noboru Sasaki; Nozomu Yokoyama; Kensuke Nakamura; Keitaro Morishita; Sangho Kim; Takafumi Sunaga; Mitsuyoshi Takiguchi
ACVIM FORUM 2024, 06 Jun. 2024, American College of Veterinary Internal Medicine, English
Minneapolis, United States - 急性骨髄性白血病あるいは骨髄異形成症候群が疑われた猫の１例
菅原 芽伊
第10回日本獣医輸血研究会×小動物臨床血液研究会, 26 May 2024, 小動物臨床血液研究会
東京, Japan - 〔主要な業績〕ケースカンファレンス「血液疾患」 再生不良性貧血と診断した犬の１例
菅原芽伊; 山口敬央; 森下啓太郎
第20回日本獣医内科学アカデミー, 24 Feb. 2024
23 Feb. 2024 - 25 Feb. 2024 - モルヌピラビル治療中におけるMRI 検査所見の変化を追った中枢神経型猫伝染性腹膜炎の1例
片山 蒼; 笹岡一慶; 新坊弦也; 紀田 泉; 中村隼人; 前川直也; 松野啓太; 菅原芽伊; 横山 望; 佐々木東; 森下啓太郎; 中村健介; 滝口満喜
第20回日本獣医内科学アカデミー, 24 Feb. 2024, 日本獣医内科学アカデミー
23 Feb. 2024 - 25 Feb. 2024, 東京, Japan - 一過性の前庭徴候を呈した犬 30 例の臨床的特徴と診断(2016-2023)
山口敬央; 笹岡一慶; 大田寛; 新坊弦也; 菅原芽伊; 横山望; 佐々木東; 森下啓太郎; 中村健介; 滝口満喜
第20回日本獣医内科学アカデミー, 24 Feb. 2024, 日本獣医内科学アカデミー
23 Feb. 2024 - 25 Feb. 2024, 東京, Japan - 治療中に神経症状を呈し、 モルヌピラビルの増量により寛解した非滲出型猫伝染性腹膜炎の猫の1例
前田和花; 森下啓太郎; 笹岡一慶; 菅原芽伊; 横山望; 佐々木東; 中村健介; 滝口満喜
第20回日本獣医内科学アカデミー, 24 Feb. 2024, 日本獣医内科学アカデミー
23 Feb. 2024 - 25 Feb. 2024, 東京, Japan - 〔主要な業績〕PIMAに対する治療法の検討
菅原 芽伊
第20回日本獣医内科学アカデミー, 23 Feb. 2024, 日本獣医内科学アカデミー
23 Feb. 2024 - 25 Feb. 2024, 東京, Japan - 病理組織学的に慢性胆嚢炎と診断された犬 43 頭の超音波検査所見
越田凜太郎; 横山望; 賀川由美子; 菅原芽伊; 笹岡一慶; 新坊弦也; 佐々木東; 森下啓太郎; 中村健介; 滝口満喜
第20回日本獣医内科学アカデミー, 23 Feb. 2024, 日本獣医内科学アカデミー, Oral presentation
23 Feb. 2024 - 25 Feb. 2024, 東京, Japan - 結腸の肉芽腫切除とモルヌピラビルで寛解を得た猫伝染性腹膜炎の一例
澤村飛龍; 横山望; 尚昊; 菅原芽伊; 笹岡一慶; 新坊弦也; 佐々木東; 森下啓太郎; 中村健介; 滝口満喜
第20回日本獣医内科学アカデミー, 23 Feb. 2024, 日本獣医内科学アカデミー, Oral presentation
23 Feb. 2024 - 25 Feb. 2024, 東京, Japan - 〔主要な業績〕Comprehensive protein and gene expression analysis of spleen from dogs with non-regenerative immune-mediated anemia
Mei Sugawara-Suda; Jumpei Yamazaki; Keitaro Morishita; Kenyu Imai; Sangho Kim; Kenji Hosoya; Noboru Sasaki; Kensuke Nakamura; Mitsuyoshi Takiguchi
American College of Veterinary Internal Medicine Forum 2022, Jun. 2022, Poster presentation - クッシング症候群と肝細胞癌のイヌにおけるステロイドプロファイルの包括的解析
OO Thandar; 佐々木東; 池中良徳; 永田矩之; 一瀬貴大; BIN Teoh Yong; 川元誠; 小島一輝; 菅原芽伊; 中山翔太; 石塚真由美; 中村健介; 滝口満喜
第164回日本獣医学会学術集会, Sep. 2021 - 非再生性免疫介在性貧血の犬における脾臓摘出術前後の血清中蛋白の網羅的解析
菅原芽伊; 山崎淳平; 森下啓太郎; 金 尚昊; 細谷謙次; 佐々木 東; 中村健介; 滝口満喜
第164回日本獣医学会学術集会, Sep. 2021, Oral presentation - Serum proteome of dogs with Non-regenerative immune-mediated anemia before and after splenectomy
Mei SUGAWARA; Jumpei YAMAZAKI; Keitaro MORISHITA; Songho KIM; Kenji HOSOYA; Noboru SASAKI; Kensuke NAKAMURA; Mitsuyoshi TAKIGUCHI
The 9th Sapporo Summer Seminar for One Health, Sep. 2021, Poster presentation - Treatment results of splenectomy for 11 cases of idiopathic non-regenerative anemia in Miniature Dachshunds
Mei SUGAWARA; Keitaro MORISHITA; Noboru SASAKI; Kenji HOSOYA; Yumiko KAGAWA; Mitsuyoshi TAKIGUCHI
The 8th Sapporo Summer Seminar for One Health, Sep. 2020, Poster presentation - 〔主要な業績〕非再生性貧血のミニチュア・ダックスフンド11例に対する脾臓摘出術の治療成績
菅原芽伊; 森下啓太郎; 今井健友; 山崎淳平; 佐々木 東; 大田 寛; 細谷謙次; 滝口満喜
第16回日本内科学アカデミー学術大会, Feb. 2019, Oral presentation - 犬の免疫介在性血小板減少症における好発品種およびその臨床的特徴
菅原芽伊; 谷 章禎; 富安博隆; 大参亜紀; 大野耕一; 辻本 元
第15回日本内科学アカデミー学術大会, Feb. 2019, Oral presentation - T-cell-rich large B-cell lymphoma の猫の2例
菅原芽伊; 大参亜紀; 佐藤 茜; 佐野頼典; 坪井誠也; チェンバーズ・ジェームズ; 内田和幸; 富安博隆; 後藤(越野)裕子; 大野耕一; 辻本 元
第15回日本内科学アカデミー学術大会, Feb. 2019, Oral presentation - NK 細胞性リンパ腫/白血病の猫の1 例
平林美幸; チェンバーズ ジェームズ; 菅原芽伊; 大参亜紀; 辻本 元; 中山裕之; 内田和幸
第5回日本獣医病理学専門家協会学術集会, Mar. 2018, Poster presentation - 6 種類の検査項目に基づいた犬における新たなDIC 診断基準確立の試み.
菅原芽伊; 大参亜紀; 横山 望; 中川泰輔; 富安博隆; 大野耕一; 辻本 元
第14回日本内科学アカデミー学術大会, Feb. 2018, Oral presentation - 猫における播種性血管内凝固(DIC)の発生とトロンビン–アンチトロンビン複合体(TAT)測定の有用性に関する検討
菅原芽伊; 大参亜紀; 富安博隆; 竹田沙和子; 加藤大貴; 辻本 元
第13回日本内科学アカデミー学術大会, Feb. 2017, Oral presentation - The Influence of Aging and Sex on Anesthetic Induction with Alfaxalone or Propofol in Dogs.
Sugawara M, Tamura J, Endo Y, Higuchi C, Umar M, Miyoshi K, Sano T, Yamashita K.
World Congress of Veterinary Anaesthesiology 2015, Sep. 2015, Poster presentation - 犬臨床例におけるアルファキサロンとプロポフォールの静脈内 投与による麻酔導入の効果の比較
菅原芽伊; 田村 純; 遠藤雄介; 川瀬広大; 福井 翔; 大山紀彦; 樋口千佳; 佐野忠士; 三好健二郎; 山下和人
第90 回日本獣医麻酔外科学会, Jun. 2015, Oral presentation
■ Academic and Social Contribution Activities/Other
Social Contribution Activities
